Participated · Equity · Jun 2021

FineHeart is a clinical-stage medical device company headquartered in Bordeaux and Tours that is building FlowMaker®, the first fully implantable cardiac output accelerator designed for advanced heart failure. The intraventricular pump synchronizes with native heart contractions, preserves physiological blood flow, and is wirelessly recharged via transcutaneous energy transfer, sharply lowering infection risk. Implantation is performed on a beating heart through a minimally invasive 90-minute procedure, giving surgeons a familiar workflow. The technology addresses a market of about 200,000 patients a year and initially targets the 50,000 most severe cases not served by current LVADs, an opportunity valued at more than €5 billion. FineHeart protects its platform with 160 patents across 27 families. With the latest funding, the company plans to industrialize FlowMaker® hardware, run clinical trials, and solidify its leadership in active implantable medical devices (AIMDs).